Evolution of Diagnoses, Survival, and Costs of Oncological Medical Treatment for Non-Small-Cell Lung Cancer over 20 Years in Osona, Catalonia

Evolution of Diagnoses, Survival, and Costs of Oncological Medical Treatment for Non-Small-Cell Lung Cancer over 20 Years in Osona, Catalonia

Non-small-cell lung cancer (NSCLC) has experienced several diagnostic and therapeutic changes over the past two decades. However, there are few studies conducted with real-world data regarding the evolution of the cost of these new drugs and the corresponding changes in the survival of these patient...

Full description

Saved in:
Bibliographic Details
Published in:Current oncology (Toronto) Vol. 31; no. 4; pp. 2145 - 2157
Main Authors: Parera Roig, Marta, Colomé, David Compte, Colomer, Gemma Basagaña, Sardo, Emilia Gabriela, Tournour, Mauricio Alejandro, Fernández, Silvia Griñó, Ominetti, Arturo Ivan, Juvanteny, Emma Puigoriol, Polo, José Luis Molinero, Jobal, Daniel Badia, Espejo-Herrera, Nadia
Format: Journal Article
Language:English
Published: Switzerland MDPI AG 01-04-2024
Subjects:
Aged
Analysis
Cancer
cancer survival
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - economics
Carcinoma, Non-Small-Cell Lung - mortality
Chemotherapy
Economic aspects
Epidemiology
Female
Health aspects
Health Care Costs
health economics
Humans
Immunotherapy
lung cancer
Lung cancer, Non-small cell
Lung Neoplasms - drug therapy
Lung Neoplasms - economics
Lung Neoplasms - mortality
Male
Medical economics
Medical research
Medicine, Experimental
Middle Aged
NSCLC: non-small-cell lung cancer
oncological treatment costs
Pemetrexed
real-world data
Retrospective Studies
Spain
Spain
lung cancer
oncological treatment costs
real-world data
NSCLC: non-small-cell lung cancer
cancer survival
health economics
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Non-small-cell lung cancer (NSCLC) has experienced several diagnostic and therapeutic changes over the past two decades. However, there are few studies conducted with real-world data regarding the evolution of the cost of these new drugs and the corresponding changes in the survival of these patients. We collected data on patients diagnosed with NSCLC from the tumor registry of the University Hospital of Vic from 2002 to 2021. We analyzed the epidemiological and pathological characteristics of these patients, the diverse oncological treatments administered, and the survival outcomes extending at least 18 months post-diagnosis. We also collected data on pharmacological costs, aligning them with the treatments received by each patient to determine the cost associated with individualized treatments. Our study included 905 patients diagnosed with NSCLC. We observed a dynamic shift in histopathological subtypes from squamous carcinoma in the initial years to adenocarcinoma. Regarding the treatment approach, the use of chemotherapy declined over time, replaced by immunotherapy, while molecular therapy showed relative stability. An increase in survival at 18 months after diagnosis was observed in patients with advanced stages over the most recent years of this study, along with the advent of immunotherapy. Mean treatment costs per patient ranged from EUR 1413.16 to EUR 22,029.87 and reached a peak of EUR 48,283.80 in 2017 after the advent of immunotherapy. This retrospective study, based on real-world data, documents the evolution of pathological characteristics, survival rates, and medical treatment costs for NSCLC over the last two decades. After the introduction of immunotherapy, patients in advanced stages showed an improvement in survival at 18 months, coupled with an increase in treatment costs.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1718-7729
1198-0052
1718-7729
DOI:10.3390/curroncol31040159